Philip Hall to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Philip Hall has written about Leukemia, Myeloid, Acute.
Connection Strength
0.783
-
Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anticancer Drugs. 2008 Nov; 19(10):1007-11.
Score: 0.280
-
Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy. Pharmacotherapy. 2005 Aug; 25(8):1134-40.
Score: 0.224
-
DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999 Apr; 13(4):629-33.
Score: 0.144
-
The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60.
Score: 0.114
-
Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug; 54(8):799-806.
Score: 0.013
-
Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells. Leuk Res. 1997 Jul; 21(7):681-90.
Score: 0.008